Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.
Non-Hodgkin lymphoma statistics
New cases of non-Hodgkin lymphoma, 2014, UK
Deaths from non-Hodgkin lymphoma, 2014, UK
Survive non-Hodgkin lymphoma for 10 or more years, 2010-11, England and Wales
Preventable cases of non-Hodgkin lymphoma, UK
- There were around 13,600 new cases of non-Hodgkin lymphoma (NHL) in the UK in 2014, that’s 37 cases diagnosed every day.
- NHL is the sixth most common cancer in the UK (2014).
- NHL accounts for 4% of all new cases in the UK (2014).
- In males in the UK, NHL is the seventh most common cancer, with around 7,500 cases diagnosed in 2014.
- In females in the UK, NHL is the seventh most common cancer, with around 6,100 cases diagnosed in 2014
- Around half (49%) of non-Hodgkin lymphoma cases in the UK each year are diagnosed in people aged 70 and over (2012-2014).
- Incidence rates for non-Hodgkin lymphoma in the UK are highest in people aged 85-89 (2012-2014).
- Since the late 1970s, non-Hodgkin lymphoma incidence rates have more than doubled (160% increase) in Great Britain. The increase is similar in females (161% increase) and in males (154% increase).
- Over the last decade, non-Hodgkin lymphoma incidence rates have increased by almost a fifth (18%) in the UK, with a similar increase in males (18%) and females (17%).
- Most non-Hodgkin lymphoma cases are diagnosed at a late stage.
- Incidence rates for non-Hodgkin lymphoma are projected to fall by 2% in the UK between 2014 and 2035, to 26 cases per 100,000 people by 2035.
- 1 in 48 men and 1 in 58 women will be diagnosed with NHL (all subtypes combined) during their lifetime.
- Non-Hodgkin lymphoma in England is more common in females living in the most deprived areas. There is no association for males.
- NHL is as common in White, Asian and Black people.
- In the UK around 46,000 people were still alive at the end of 2006, up to ten years after being diagnosed with Non-Hodgkin lymphoma (all subtypes combined).
- In Europe, around 93,500 new cases of NHL were estimated to have been diagnosed in 2012. The UK incidence rate is ninth highest in Europe for males and eighth highest for females.
- Worldwide, nearly 386,000 new cases of NHL (all subtypes combined) were estimated to have been diagnosed in 2012, with incidence rates varying across the world.
- There were around 4,800 non-Hodgkin lymphoma (NHL) deaths in the UK in 2014, that’s 13 deaths every day.
- NHL is the 10th most common cause of cancer death in the UK (2014).
- NHL accounts for 3% of all cancer deaths in the UK (2014).
- In males in the UK, NHL is the 12th most common cause of cancer death, with around 2,600 deaths in 2014.
- In females in the UK, NHL is the eighth most common cause of cancer death, with around 2,200 deaths in 2014.
- Almost 6 in 10 (56%) non-hodgkin lymphoma (NHL) deaths in the UK each year are in people aged 75 and over (2012-2014).
- Mortality rates for NHL in the UK are highest in people aged 90+ (2012-2014).
- Since the early 1970s, non-Hodgkin lymphoma (NHL) mortality rates have increased by more than four-fifths (83%) in the UK. The increase is larger in males (87%), than in females (76%).
- Over the last decade, NHL mortality rates have decreased by almost a tenth (8%) in the UK, with a similar decrease in males (6%) and females (10%).
- Mortality rates for non-Hodgkin lymphoma are projected to fall by 20% in the UK between 2014 and 2035, to 8 deaths per 100,000 people by 2035.
- Non-Hodgkin lymphoma deaths in England are more common in females living in the most deprived areas. There is no association for males.
- In Europe, around 37,900 people were estimated to have died from NHL in 2012. The UK mortality rate is sixth highest in Europe for males and eighth highest for females.
- Worldwide, more than 199,000 people were estimated to have died from NHL (all subtypes combined) in 2012, with mortality rates varying across the world.
- Almost two-thirds (63%) of people diagnosed with Non-Hodgkin lymphoma in England and Wales survive their disease for ten years or more (2010-11).
- Around 7 in 10 (69%) of people diagnosed with Non-Hodgkin lymphoma cancer in England and Wales survive their disease for five years or more (2010-11).
- 8 in 10 (80%) of people/men/women diagnosed with Non-Hodgkin lymphoma cancer in England and Wales survive their disease for one year or more (2010-11).
- Non-Hodgkin lymphoma survival is similar in men than women.
- Non-Hodgkin lymphoma survival in England is highest for people diagnosed aged under 40 (2009-2013).
- Almost 9 in 10 people in England diagnosed with Non-Hodgkin lymphoma aged 15-39 survive their disease for five years or more, compared with more than 4 in 10 people diagnosed aged 80 and over (2009-2013).
- Non-Hodgkin lymphoma survival is improving and has tripled in the last 40 years in the UK.
- In the 1970s, more than a fifth of people diagnosed with Non-Hodgkin lymphoma cancer survived their disease beyond ten years, now it's almost two-thirds.
- When diagnosed at its earliest stage, 7 in 10 people with Non-Hodgkin lymphoma will survive their disease for five years or more, compared with less than 6 in 10 of people when diagnosed at the latest stage.
- A person’s risk of developing cancer depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
- 6% of non-Hodgkin lymphoma (all subtypes combined) cases each year in the UK are linked to major lifestyle and other risk factors.
- Evidence on NHL risk factors is limited, mainly because of the relative rarity and diversity of this group of cancers.
- An estimated 4% of NHL cases in the UK are linked to infections (mainly H. pylori).
- Certain occupational exposures and medications cause NHL.
- Ionising radiation, problems with the immune system, and overweight and obesity (for some NHL types) may relate to higher NHL risk.
- 'GP referral' is the most common route to diagnosing non-Hodgkin lymphoma (NHL).
- 'Two week wait' is the route with the highest proportion of cases diagnosed at an early stage, for NHL.
- ‘Two-week wait’ and ’31-day wait’ standards are met by all countries, and ‘62-day wait’ is not met by any country for haematological cancers.
- 8 in 10 patients with NHL are treated with chemotherapy.
- More than 9 in 10 patients had a ‘very good’ or ‘excellent’ patient experience.
- More than 8 in 10 patients are given the name of their Clinical Nurse Specialist.
The latest statistics available for non-Hodgkin lymphoma (NHL) are; incidence 2014, mortality 2014 and survival 2010-2011 (all ages combined) and 2009-2013 (by age).
The ICD codes for NHL survival are ICD-10 C82-C85.
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
NHL statistics by subtype are provided for the Haematological Malignancy Research Network (HMRN) region. HMRN covers a population of 3.6 million and is set within the former adjacent UK Cancer Networks of Yorkshire and the Humber & Yorkshire Coast England. While HMRN may not be fully representative of the country as a whole due to variation in local healthcare provision standards and policies, the population does have a similar socio-demographic profile to the UK.
Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2012.
Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages,
Overall, the evidence on NHL risk factors is limited, mainly because of the relative rarity and diversity of this cancer type; most research examines immune system-related factors.
Routes to diagnosis statistics were calculated from cases of cancer registered in England which were diagnosed in 2012-2013. Staging proportions only include patients with a known stage (cases with an unknown stage at diagnosis are not included in the denominator).
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. NHL is part of the group 'Haematological cancers' for cancer waiting times data. Codes vary per country but broadly include: Hodgkin lymphoma, follicular and non-follicular lymphoma, mature T/NK-caell lymphoma, other and unspecified types of NHL, other and unspecified types of T/NK-cell lymphoma, malignant immunoproliferative diseases, myeloma, lymphoid, myeloid and monocytic leukaemia, some other leukaemia of specific or unspecified cell type, and other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.
You are welcome to reuse this Cancer Research UK statistics content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
We would like to thank the following people for their kind help and expert advice: Dr Alex Smith and Professor Eve Roman, Haematological Malignancy Research Network (HMRN, funded by Leukaemia & Lymphoma Research); Dr Hamish Ross, National Cancer Intelligence Network (NCIN) haematology; Site-Specific Clinical Reference Group (which is hosted by Public Health England); Dr Steven Oliver, Knowledge and Intelligence Team (Northern & Yorkshire) on behalf of the NCIN; Dr Russell Patmore, Queens Centre for Oncology and Haematology, Castle Hill Hospital; and Dr Debra Howell, HMRN. However, the contents are entirely the responsibility of Cancer Research UK.
We would also like to acknowledge the essential work of the cancer registries in the United Kingdom and Ireland Association of Cancer Registries, without which there would be no data.